… ProQR update and additional sepofarsen Illuminate trial analyses ProQR has announced the … unmet need. We are also sharing additional analyses of the sepofarsen *Illuminate* trial. ProQR has announced the …
ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
… may become a very exciting year for Patricia Biasutto, sepofarsen captain. The work of her department, aimed at … to use this 3D organoid model and with it show that sepofarsen does exactly what we hoped it does in the closest …
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
